Semenikhina Marharyta, Mathew Roy O, Barakat Munsef, Van Beusecum Justin P, Ilatovskaya Daria V, Palygin Oleg
Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Division of Nephrology, Department of Medicine, VA Loma Linda Healthcare System, Loma Linda, California, USA.
Am J Hypertens. 2025 Jan 16;38(2):85-96. doi: 10.1093/ajh/hpae120.
Hypertension (HTN) is one of the key global cardiovascular risk factors, which is tightly linked to kidney health and disease development. Podocytes, glomerular epithelial cells that play a pivotal role in maintenance of the renal filtration barrier, are significantly affected by increased glomerular capillary pressure in HTN. Damage or loss of these cells causes proteinuria, which marks the initiation of the HTN-driven renal damage. It goes without saying that effective blood pressure (BP) management should not only mitigate cardiovascular risks but also preserve renal function by protecting podocyte integrity. This review offers a comprehensive examination of current BP management strategies and their implications for podocyte structure and function and emphasizes strategies for the reduction of proteinuria in HTN. We explore primary and secondary antihypertensive agents, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics, as well as newer therapies (sodium-glucose cotransporter-2 blocking and endothelin receptor antagonism), emphasizing their mechanistic roles in safeguarding podocytes and curtailing proteinuria.
高血压(HTN)是全球主要的心血管危险因素之一,与肾脏健康和疾病发展密切相关。足细胞是肾小球上皮细胞,在维持肾脏滤过屏障中起关键作用,在高血压中,肾小球毛细血管压力升高会对其产生显著影响。这些细胞的损伤或丢失会导致蛋白尿,这标志着高血压驱动的肾脏损伤的开始。不言而喻,有效的血压(BP)管理不仅应减轻心血管风险,还应通过保护足细胞完整性来维持肾功能。本综述全面审视了当前的血压管理策略及其对足细胞结构和功能的影响,并强调了降低高血压患者蛋白尿的策略。我们探讨了一线和二线抗高血压药物,包括血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、钙通道阻滞剂和利尿剂,以及新型疗法(钠-葡萄糖协同转运蛋白2阻断和内皮素受体拮抗),强调它们在保护足细胞和减少蛋白尿方面的作用机制。